- Details
- Andrea Miyahira speaks with Geraldine Gueron and Agustina Sabater about a paper on neuroendocrine prostate cancer. The discussion focuses on the development of a seven-gene stemness signature that predicts cancer progression. Using machine learning algorithms and multiple data sets, they create a risk-score model that shows significant prognostic value across different stages of prostate cancer, i...
|
- Details
- Christian Gratzke discusses the Phase III trial of opevesostat, a CYP11A1 inhibitor, for metastatic castration-resistant prostate cancer (mCRPC). The study examines opevesostat's unique mechanism of targeting androgen biosynthesis upstream of current treatments, potentially offering more complete testosterone suppression than existing therapies. The ongoing 1,500-patient trial compares opevesostat...
|
- Details
- Oliver Sartor discusses the ProstACT GLOBAL trial design, examining TLX591, a PSMA-targeting antibody bound to lutetium-177 for metastatic castration-resistant prostate cancer treatment. The phase III trial includes a 30-patient safety lead-in followed by a 400-patient randomized study comparing standard of care (ARPI switch or docetaxel) with or without TLX591. Unlike other PSMA-targeted therapie...
|
- Details
- Diane Newman discusses with Kristine Talley the RESTORE study examining urinary incontinence symptoms in gay and bisexual prostate cancer survivors, marking the first comprehensive examination of this understudied population. The research, funded by the National Cancer Institute, analyzes data from 400 men with a mean age of 63.5 years, revealing that 43% experience daily incontinence. While the t...
|
- Details
- Neeraj Agarwal discusses FOXA1 alterations in prostate cancer with Emmanuel Antonarakis and Justin Hwang, exploring research that identifies FOXA1 mutations in 15% of prostate cancers, with higher prevalence in Asian (25%) and Black (20%) patients. Their Minnesota classification system reveals that different FOXA1 mutations can lead to opposing clinical outcomes: some variants enhance hormone sens...
|
- Details
- Zachary Klaassen speaks with Neeraj Agarwal about the Phase III randomized MEVPRO-1 study examining mevrometostat in combination with enzalutamide for mCRPC patients previously treated with abiraterone acetate. Dr. Agarwal explains that EZH2, a key component of the Polycomb Repressive Complex II, functions by adding methyl groups to histone proteins, leading to gene silencing. The trial randomizes...
|
- Details
- Andrea Miyahira interviews Xiaolin Zhu about a publication examining genomic and transcriptomic features of androgen receptor signaling inhibitor (ARSI) resistance in metastatic castration-resistant prostate cancer. Through analysis of paired metastatic biopsies taken before ARSI treatment and at disease progression, Dr. Zhu's team identifies three significant findings: a novel amplified enhancer...
|
- Details
- Daniel Childs discusses real-world outcomes of lutetium-PSMA-617 treatment in prostate cancer patients with liver metastases, based on Mayo Clinic registry data. Dr. Childs presents findings showing that patients with liver metastases experience shorter overall survival (approximately 8.3 months), complete fewer treatment cycles, and demonstrate lower PSA response rates compared to those without l...
|
- Details
- Mindy Graham discusses findings from her research on MYC-driven prostate cancer, recently published in Nature Communications. Using single-cell RNA sequencing and immunostaining, Dr. Graham's team reveals how MYC activation drives consistent changes in the tumor microenvironment across both human and mouse models of prostate cancer. The research demonstrates a surprising transition from an initial...
|
- Details
- Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann presents data showing that tumor-absorbed dose per injected activity decreases significantly across treatment cycles, with approximately 60% of cumulative absorbed dose occurring in the first two cycles. He explores differences i...
|
